Latest News
AstraZeneca signs global licence deal with Dizal for lung cancer drug Zegfrovy
14 July 2026 - Biopharmaceutical company AstraZeneca PLC (STO: AZN; LON: AZN; NYSE: AZN) announced on Tuesday that it has agreed an exclusive worldwide licence with China's Dizal Pharmaceutical Co., Ltd (SSE: 688192) for Zegfrovy (sunvozertinib)...
Summit Therapeutics sells Phase III antibiotic asset ridinilazole to Biossil
14 July 2026 - Biopharmaceutical oncology company Summit Therapeutics Inc (NASDAQ:SMMT) on Tuesday announced an agreement to sell ridinilazole, an investigational Phase III precision antibiotic, to Toronto-based Biossil Inc, an AI-native biopharma co...
European Commission approves Erbitux combination for first-line BRAF V600E-mutant mCRC
14 July 2026 - US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, announced on Tuesday that the European Commission has approved an updated label for Erbitux (cetuximab), allowing its use in combination w...
Servier acquires Edgewise Therapeutics' muscular dystrophy business
14 July 2026 - French pharmaceutical company Servier announced on Monday that it has completed the acquisition of the muscular dystrophy business of Edgewise Therapeutics Inc (Nasdaq:EWTX) following regulatory clearance and customary closing conditio...
US FDA accepts BioMarin's sNDA for full approval of VOXZOGO (vosoritide) for children with achondroplasia
14 July 2026 - Rare disease biotechnology company BioMarin Pharmaceutical Inc (Nasdaq:BMRN) announced on Monday that the US Food and Drug Administration (FDA) has accepted the company's supplemental New Drug Application (sNDA) for VOXZOGO (vosor...